Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xia Li
Institution:
Liaoning Cancer Hospital & Institute
Observed institution:
Liaoning Cancer Hospital & Institute
ORCID:
0009-0001-2573-2406
Observed ORCID:
0009-0001-2573-2406
OpenAlex ID:
A5138774231
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
2026
·
Liqiong Xue
, Yaqian Han
, et al.
·
Clinical Cancer Research
·
6
A multicenter, real-world study analysis: pembrolizumab changes treatment strategy for the patient with recurrent/metastatic head and neck squamous cell carcinoma
2025
·
Man Hu
, Xia Li
, et al.
·
Cancer Letters
·
2
A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
2024
·
Man Hu
, Shichuan Zhang
, et al.
·
Journal of Clinical Oncology
·
2
Supplementary Data 2 from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
2026
·
Liqiong Xue
, Yaqian Han
, et al.
Supplementary Data 1 from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
2026
·
Liqiong Xue
, Yaqian Han
, et al.
Data from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
2026
·
Liqiong Xue
, Yaqian Han
, et al.
Show more works
View as search
Works count:
6
Citation count:
10
H-index:
2
I10-index:
Year
Topic
Type